Audit-Ready PGx Reporting: What Your Lab Must Document

An audit-ready pharmacogenomics (PGx) report is one where every statement can be traced: the method that produced the genotype, the variant and nomenclature behind the phenotype, the guideline and version behind each recommendation, and the named person who reviewed and signed it. If an inspector, a medical director or a hospital pharmacy committee asks why a report said what it said on a given date, your lab should be able to answer from the record alone. This guide sets out what that record contains, how to validate the workflow that generates it, and how to keep it defensible as CPIC, DPWG and FDA content changes.

SignalPGx

Make PGx Reports Easier to Trace

SignalPGx combines genotype data, medication histories and clinical evidence into physician-reviewed reports designed for modern laboratories.

Visit SignalPGx

TL;DR

Audit-ready means reproducible: every report links genotype, phenotype, drug recommendation, evidence source and version, and the signing reviewer.
Published standards from ACMG and AMP define minimum report content, nomenclature and CLIA-aligned quality oversight; build your template from them.
Document test methods and limitations, detected variants, interpretation references, report dates and the laboratory director's signature.
Evidence moves continuously, so versioned sources and a defined reanalysis process matter as much as the first report.
Automation helps only when it preserves the audit trail and leaves final approval with a qualified human reviewer.

What audit-ready means for a PGx report
The content an auditor expects on the report itself
The documentation your lab keeps behind the report
Validating the workflow, not just the assay
Evidence versioning and reanalysis
Our perspective: the audit trail is a design decision
Integrating with LIS and EHR without losing the trail
Privacy, security and jurisdiction
How SignalPGx supports an audit-ready workflow
A short self-audit for your lab
FAQ
Sources

What audit-ready means for a PGx report

Pharmacogenomics studies how a person's DNA affects response to medications, which helps providers predict effective drugs and doses while reducing adverse reactions, as the National Human Genome Research Institute explains. A PGx report is the artifact through which that science reaches a prescriber. That makes it a clinical document with a clinical risk profile, and it will be read by people who were not in your lab when it was produced.

Audit readiness is therefore a property of the whole chain, not of the PDF. Three questions define it:

Can you reconstruct it? Given a report from last year, can you identify the raw genotype call, the allele definitions, the phenotype translation and the guideline text that were in force?
Can you show who decided? Was the output reviewed and signed by an accountable director, and is that review recorded with a timestamp?
Can you show what changed? If a recommendation was updated later, is it clear what triggered the change, which patients were affected and who was notified?

There is no single regulation titled PGx audit requirements. What exists is a set of overlapping expectations: CLIA-style quality management, professional society standards for report content, accreditation checklists, and privacy law. Preparing for an audit means mapping your documentation to each of them.

The content an auditor expects on the report itself

The most concrete guidance comes from professional bodies. The ACMG 2021 technical standard for clinical pharmacogenomic testing and reporting calls for Human Genome Organisation (HUGO) gene nomenclature and Human Genome Variation Society (HGVS) nomenclature for sequence variants. It also states that reports should disclose that drug-drug interactions can alter predicted metabolizer phenotypes. The Association for Molecular Pathology's 2019 position statement on PGx best practices asks for metabolizer status, a list of affected drugs, a generalized statement on alternative treatments, and resources for clinical decision-making.

An international survey of molecular diagnostic laboratories found that nomenclature and methodology descriptions were the elements most often needing standardization, according to the IFCC harmonization work. Those are exactly the fields where auditors find inconsistencies between reports issued months apart.

The table below turns these requirements into a practical template review.

Report element	What to show	Why an auditor asks
Gene and variant nomenclature	HUGO gene symbols, HGVS for sequence variants	Unambiguous identification across systems
Genotype and metabolizer status	Detected diplotype and the derived phenotype	Links raw result to clinical meaning
Affected drugs	Drug list tied to the gene-drug pair in scope	Shows the report covers what it claims
Recommendation and alternatives	Guideline-based action, plus a general statement on alternative treatment	Supports the prescriber's decision
Interaction disclosure	Statement that drug-drug interactions can alter predicted phenotype	Prevents overreading of genotype alone
Method and limitations	Assay, what is and is not detected	Defines the boundaries of the result
Evidence references	Guideline or label source, with version	Makes the recommendation traceable
Dates and signature	Report date, reviewing director's signature	Establishes accountability

Two cautions apply to presentation. First, a 2024 review of pharmacogenomic test interpretation advises clinicians not to rely solely on laboratory color-coding such as green, yellow and red, because it can oversimplify complex drug-gene interactions. If your reports use color, pair it with the underlying phenotype and the text of the recommendation so nothing depends on the color alone. Second, the same review notes that age, renal function and concomitant medications can supersede PGx data, so the report should invite integration into the broader clinical picture rather than imply that the genotype decides.

The documentation your lab keeps behind the report

A report can be perfect and the lab still fail an audit if the supporting record is thin. A 2024 clinical pharmacogenetic testing review in Annals of Laboratory Medicine says laboratories should document test methods and limitations, detected variants and genotypes, interpretation references, report dates and the interpreting laboratory director's signature. Use that as the spine of a per-report record.

In practice, we suggest the record for each issued report contains:

Specimen and assay provenance: accession, platform, assay version, and run identifiers.
Variant-level results: the calls that fed the interpretation, including any no-call or indeterminate results and how they were handled.
Interpretation logic version: the allele-function tables, phenotype translation rules and recommendation text in effect on the report date.
Evidence references: the specific guideline, drug label or database entry cited, with its version or retrieval date.
Medication context: the medication list used at the time, because a medication simulation or interaction note depends on it.
Review trail: who reviewed, what was changed from the automated draft, who signed, and when.
Distribution log: where the report went, in what format, and any later amendments.

The AMP statement also expects PGx testing providers to comply with CLIA regulations, including documented analytical validity, a robust quality management system and oversight by board-certified molecular laboratory professionals. That oversight should be visible in the record, not assumed. If a director signs a report, your system should show what they saw when they signed it.

Validating the workflow, not just the assay

Most labs know how to validate a genotyping assay. Fewer treat the interpretation and report-generation layer with the same rigor, and that layer is where an audit-ready claim is won or lost.

The ACMG technical standard says workflows should be validated for accuracy, precision, analytical sensitivity and specificity, and reportable range, and that accuracy evaluation should use at least 20 previously characterized samples (see the ACMG standard). Apply the same discipline to software: run characterized samples through the full pipeline, from genotype input to final report text, and keep the expected-versus-observed comparison as a controlled document.

Genotype workflow and report validation comparison

A 2025 review in the Journal of Laboratory and Precision Medicine adds two points worth building into your plan. Clinical validation of PGx platforms calls for coordination among laboratory, pharmacy and clinical teams, often using IRB-approved study data. And for custom platforms, the authors argue for a more rigorous validation plan that challenges analytical accuracy and precision beyond standard requirements. If your lab has configured its own rules or templates, treat that configuration as custom.

A workable validation package for the reporting layer includes:

A written specification of every gene-drug pair in scope and the source of each rule.
Test cases covering normal, intermediate, poor, rapid and ultrarapid phenotypes where applicable, plus ambiguous and no-call inputs.
Concordance between automated output and a manual expert interpretation.
Acceptance criteria agreed before testing, and signed results.
Change control: any rule or template change triggers a documented impact assessment and, where warranted, revalidation.

For complex cases, such as patients on several interacting drugs, see our guide on building polypharmacy PGx reporting, since interaction logic is a frequent validation gap.

Evidence versioning and reanalysis

This is the area where manual processes quietly erode audit readiness. The Annals of Laboratory Medicine review says laboratories should review current sources, including CPIC, DPWG, PharmGKB and FDA drug labels, because evidence and recommendations keep emerging. A 2014 review of PGx implementation reports that CPIC guidelines are evaluated for updates approximately every two years, and that CPIC describes its development process publicly to meet transparency standards. Updates are a normal event, not an exception.

Content changes can also remove a recommendation entirely. The open-source PharmCAT changelog records that version 2.11.0 removed F5 after DPWG withdrew its recommendation for F5 and systemic hormonal contraceptives and the PharmGKB annotation was retired. A lab that hard-coded that pair would keep issuing a recommendation its source no longer supports, and could not explain why.

To stay defensible, define these controls in writing:

A source register: each guideline, label and database you use, who owns monitoring it, and how often it is checked.
Versioned rule sets: every report stores the version of the rules that produced it.
A triage procedure: when a source changes, who decides whether it affects reports, within what time frame, and how that decision is documented.
A reanalysis policy: which previously issued reports are re-evaluated, which are only flagged, and how clinicians are notified of an amended recommendation.
Lifetime phenotype storage: the 2025 Hospital Pharmacy Europe report on pharmacy-led PGx implementation recommends that hospital PGx subcommittees maintain a formulary of in-scope drug-gene pairs and ensure lifetime discrete phenotype reporting for auditability.

We cover the downstream side of this in more depth in our article on post-analytic PGx, versioning and reanalysis.

Our perspective: the audit trail is a design decision

We build reporting infrastructure for laboratories, and the pattern we see most often is that audit readiness gets treated as a documentation exercise at the end of a project. By then the evidence is spread across spreadsheets, PDFs of guidelines and email approvals, and nobody can say which version of a CPIC table produced a report from eight months ago.

Our view is that three things should be true from day one. Evidence should be fused from authoritative sources into a single, versioned structure rather than copied by hand into templates. Every report should carry its own provenance, so the question of what was known on the report date has a mechanical answer. And automation should draft while people decide: the medical director's review and sign-out should be a recorded step, not a formality, because accountability cannot be delegated to software.

We also think labs should resist the temptation to make reports look simpler than the science. A clean layout is valuable, but the reader should always be able to reach the phenotype, the source and the caveats. That is what makes a report trustworthy to a prescriber and survivable in an audit.

— Tarek

Integrating with LIS and EHR without losing the trail

Once a report leaves the lab, its audit value depends on what happens to it. The 2025 JLPM review says reports should be available to clinicians through the EHR or a secure web portal, with results and action recommendations clearly presented. The IFCC committee goes further and suggests that heterogeneity among molecular diagnostic reports is a potential safety risk when providers merge disparate reports into an electronic health record, per the harmonization study.

The practical response is to deliver discrete, structured data alongside the readable report, so that the phenotype and the recommendation can be retrieved, not just displayed. Our guides on FHIR-ready PGx report sections and on mapping one gene-drug pair in FHIR first describe a staged way to do this without trying to model everything at once.

Audit questions to settle during integration:

Is the version of the report the clinician sees the same one the lab signed, and is any amendment visibly linked to the original?
Can the LIS and the EHR each show who accessed or changed a result?
When a reanalysis changes a recommendation, how does the update reach the chart?

The clinician side matters as well. Because genotype is only one input, systems that surface age, renal function and concomitant medications next to the PGx result support better decisions, a theme shared with EMR integration in healthcare intake workflows, where structured clinical data is brought to the point of decision rather than left in separate documents.

Privacy, security and jurisdiction

PGx data is genetic data, and the rules differ by country. In the United States, labs typically work under CLIA and HIPAA; in Europe, GDPR applies. The 2025 Hospital Pharmacy Europe piece stresses that hospital-led PGx governance should address GDPR obligations through data minimization and role-based access from the start. At a global level, a 2026 World Health Assembly resolution on precision medicine urges countries to maintain frameworks for data governance, privacy, interoperability, security and quality assurance.

For your audit file, that translates into a short set of artifacts: an access-control matrix, a record of who can see identifiable genotype data, a retention schedule that matches the rules of each jurisdiction you serve, and a data-flow diagram showing where reports and underlying genotypes are stored. Retention periods and accreditation checklists vary by state and country, so confirm them with your accrediting body and counsel instead of copying another lab's schedule.

How SignalPGx supports an audit-ready workflow

SignalPGx is pharmacogenomics reporting software for laboratories. It turns genotype and medication data into physician-reviewed, evidence-graded PGx reports, fusing evidence from 15+ authoritative sources, and it keeps your medical director in control of final approval with a review and audit trail. Living reanalysis alerts your team as guidelines evolve, integration with EHRs uses HL7/FHIR standards, and the platform is built with HIPAA and GDPR compliance in mind.

SignalPGx

Labs can deploy under their own brand through our white-label PGx reporting infrastructure, typically within 5 to 7 days. If you want to scope the work first, our project services are published as starting points: Discovery & Strategy from $7,000, System Design from $9,000 and Deployment & Integration from $15,000, each one-off per project, described on the SignalPGx site. If you are comparing vendors against your audit criteria, our PGx RFP checklist makes CPIC, CLIA and FHIR requirements testable.

A short self-audit for your lab

Before your next inspection or vendor review, answer these honestly:

Does every report use HUGO and HGVS nomenclature and disclose the drug-drug interaction caveat?
Can you retrieve, for any report, the rule set and evidence version used?
Have you validated the interpretation layer with characterized samples, not only the assay?
Is there a written policy for source monitoring and reanalysis, with named owners?
Is the director's review recorded in the system, with a timestamp?
Do your EHR deliveries preserve amendments and link back to the original?
Can you show access controls and retention rules for genetic data?

Any no is a work item. Most labs find two or three, and they are usually in the evidence versioning and review trail, not in the lab bench work.

FAQ

What are the audit requirements for PGx reporting?

There is no single PGx-specific rule. Labs are generally held to CLIA-style quality management, professional standards such as the ACMG 2021 technical standard and AMP 2019 position statement, and privacy law such as HIPAA or GDPR. Your record should show methods and limitations, detected variants, interpretation references, dates and the director's signature.

How many samples are needed to validate a PGx workflow?

The ACMG 2021 technical standard says accuracy evaluation should use at least 20 previously characterized samples, alongside precision, analytical sensitivity and specificity, and reportable range. For custom or laboratory-configured platforms, published reviews suggest going beyond that minimum. Agree acceptance criteria before testing starts.

How often should a lab update PGx recommendations?

Evidence changes continuously, so there is no single interval. CPIC guidelines are evaluated for updates approximately every two years, while DPWG, PharmGKB and FDA labels change on their own schedules. Monitor all of them under a documented process and version each report against the rules in force.

Can automated PGx reports be audit-ready?

Yes, provided automation records its inputs, rule versions and outputs, and a qualified reviewer approves each report in a logged step. Automation reduces transcription errors and speeds updates, but accountability stays with the laboratory director.